Status:
RECRUITING
Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia
Lead Sponsor:
Lingling Yu (103250)
Collaborating Sponsors:
Wuhan Integrated Traditional Chinese and Western Medicine Hospital
Xianning Central Hospital
Conditions:
Asymptomatic Hyperuricemia
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and tr...
Detailed Description
This is a multicentre, stratified, randomized, sham-controlled clinical trial. 180 eligible participants will be randomly allocated into verum acupuncture group or sham acupuncture group, in a 1:1 rat...
Eligibility Criteria
Inclusion
- Diagnosed as hyperuricemia; and
- Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and
- Without history of gouty arthritis; and
- Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and
- 5kg/m2≤BMI≤30.0kg/ m2; and
- Able to signing a informed consent.
Exclusion
- Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and
- Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and
- Patients have history of gouty arthritis; and
- Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and
- Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and
- Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and
- Pregnant women; and
- Unwilling to accept acupuncture treatment; and
- Illiterate, or patients unable to sign informed consent; and
- The completion rate of baseline screening data is ≤80%.
Key Trial Info
Start Date :
July 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05406830
Start Date
July 13 2022
End Date
December 31 2024
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030